Your Messages Inbox
Your Article Summary
See Latest ArticlesUpdate on FDA Registration of Actemra, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
Chugai Pharmaceutical Co., 09/01/09
Chugai Pharmaceutical Co., Ltd. and F. Hoffmann–La Roche Ltd. announced today that FDA has accepted the complete response resubmission that Roche made to the U.S. Food and Drug Administration for the Biologics License Application for Actemra the humanized anti–human IL–6 receptor monoclonal antibody, following the receipt of the Complete Response Letter in September 2008.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Article Search
Sponsor